🔗 Share this article

As the US continues making sweeping revisions to its vaccine guidelines, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines during the pandemic and has focused upon possible deaths after Covid immunization in her brief position at the FDA.

Planned Changes to Childhood Immunization Program

Public health authorities planned to unveil radical revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US at odds with many the international standard with little proof for public health gain. The announcement has been delayed until the coming year.

Rather than the director of the vaccine center, Høeg is listed to speak at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the office this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting some childhood immunization guidelines in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

To date comments, she has kept her attention on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no obvious track record in drug development, approval processes or management, which has been customary for former heads of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“She appears not to have any of the qualifications” for leading the CDER, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in leading a large organization. She is not an expert in drug approvals.”

Past heads of CBER would “grasp regulatory frameworks and the research of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who ran the center have had.”

CDER has an enormous portfolio at the FDA, the former commissioner stated.

“Everybody just pays attention on the new drug program, but the generic program authorizes thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those need to be looked after,” she explained. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative aspect to the job, which manages over 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” Woodcock said.

Response and Disputed Policies

Regarding concerns about Høeg’s credentials and whether this appointment indicates more teamwork among agency officials on vaccines, a spokesperson stated that the “concerns stem from inaccurate assumptions”.

“Her resume aligns with the duties of her role,” the representative explained, noting the time Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a disputed rapid drug-approval program that apparently concerned her predecessors. “By what process are these drugs being selected for this voucher program? Who is making the decisions?” Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards laxer oversight of all drugs, with the exception of shots.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more documented, if troubling, track record, critics observe. She released a analysis using non-validated public submissions to assess the rate of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed changing rules for new vaccines and ending “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has allegedly floated the idea of barring adolescent males from getting COVID-19 vaccinations.

“She is an complete true believer who commences with her conclusions and works backwards to accommodate the data in a highly disingenuous, untruthful manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|